Methods and compounds for treating proliferative disorders and viral infections
AssigneeUniversity College Dublin, National University of Ireland, Dublin
InventorsB. Therese Kinsella, Helen Reid
Life of this patent
Estimating the term…
Abstract
The invention generally relates to methods and compounds for treating proliferative disorders, viral infections, or both. In some embodiments, the invention provides an anticancer or antiviral compound including a substituted nitro phenoxy phenyl, a sulfonylurea, and an alkyl group. In some embodiments, the invention provides a method of treating a proliferative disorder or a viral infection including administering an anticancer or antiviral compound that binds to a thromboxane receptor, has preferential binding for either TPalpha (TPα) or TPbeta (TPβ) receptor subtype.
Claims24
Use of a compound for the treatment of a proliferative disorder, wherein the compound has formula (I):
- wherein:
- R1 is an alkyl group;
- and
- R2 is selected from the list consisting of a halogen, an alkyl group, and an aryl group,
- or a pharmaceutically acceptable salt thereof.
(canceled)
Use of a compound for the treatment of a proliferative disorder, wherein the compound is represented by formula (XXII):
- wherein R10 is selected from the group consisting of
- H, NH2, I,
- and CO2Me, or a pharmaceutically acceptable salt thereof.
Use of a compound for the treatment of a proliferative disorder, wherein the compound is represented by formula (XXII):
- wherein R10 is selected from the group consisting of
- and Cl,
- or a pharmaceutically acceptable salt thereof.
Use of a compound for the treatment of a proliferative disorder, wherein the compound is represented by a formula selected from the group consisting of (LVII), (LVIII), (LIX), and (LX):
- or a pharmaceutically acceptable salt thereof.
An anticancer compound that specifically binds to a thromboxane receptor and has preferential binding for either TP-alpha or TP-beta receptor subtype.
A method of treating cancer comprising administering an anticancer compound, or a pharmaceutically acceptable salt thereof, wherein the anticancer compound or the salt thereof binds preferentially to a thromboxane receptor and has preferential binding for either TP-alpha or TP-beta receptor subtype.
(canceled)
24-46. (canceled)
Dependencies are inferred from the claim text.